TRAVERE THERAPEUTICS INC (TVTX) Stock News
NASDAQ:TVTX - Nasdaq - US89422G1076 - Common Stock - Currency: USD
TVTX Latest News, Press Relases and Analysis
Guide to refinancing an FHA loan to a conventional loan
Crunch the numbers carefully to see if the switch is worth it.
BTIG Stays Bullish on Super Group (SGHC) Limited (SGHC) Amid Sportsbook Optimism
Super Group (SGHC) Limited (NYSE:SGHC) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at BTIG Research have reaffirmed the “Buy” rating on Super Group (SGHC) Limited (NYSE:SGHC), while raising the price target to $11 from $9, signaling a surge of about 18% from the current stock price. This price appreciation […]
Spectris rejects second KKR proposal in favour of Advent's $5 billion bid
Spectris did not provide details on KKR's proposal, noting only that it was the second proposal by the private equity firm it had rejected. The company, which provides hardware and software solutions to sectors such as pharmaceuticals, steel and automotive, said on Monday it would accept private equity firm Advent's proposal of 37.63 pounds per share, if a formal offer was made.
Middle East conflict threatens to exacerbate inflationary pressure on some things
Israel's attack on Iran Friday has catapulted their long-running conflict into what could become a wider, more dangerous regional war and potentially drive prices higher for both businesses and households. After years of sky-high inflation in the aftermath of the COVID-19 pandemic, Americans have become increasingly leery about the economy this year due to President Donald Trump's sweeping tariffs, though the impact so far has been muted. The latest escalation in the Middle East has the potential to cause widespread price increases that could set consumers back again.
Mentions: TELO
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a leading investment bank, has initiated a “Buy” rating for Travere Therapeutics, Inc. (NASDAQ:TVTX), with a price target of $30, signaling an upside of around 100%. This confidence in the company underscores its position in […]
TELO Rises on Promising Telomir-1 Preclinical Results
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson’s disease. In a zebrafish model mimicking Wilson’s disease, […]
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such...
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such...
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug.
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries
Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026.
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Mentions: VRCA
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Participate at Upcoming Investor Conferences
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of 14.55% and 3%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VCEL
